Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis
Francisco Javier Barrero Hernández,1– 3 Ángel José Morales Lahoz,1 Cristina Serrano Gutiérrez,1 Elena López Fandila,1 Carolina Asenjo Martín,1 Maria Dolores González Ramírez,2 Raquel Piñar-Morales1– 3 1Department of Neurology, Hospital Clinico Universitario San Cecilio, Granada, Spain; 2Department o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-03-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-practice-evidence-of-treatment-satisfaction-with-moderate-and-peer-reviewed-fulltext-article-PPA |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850094952929820672 |
|---|---|
| author | Barrero Hernández FJ Morales Lahoz ÁJ Serrano Gutiérrez C López Fandila E Asenjo Martín C González Ramírez MD Piñar-Morales R |
| author_facet | Barrero Hernández FJ Morales Lahoz ÁJ Serrano Gutiérrez C López Fandila E Asenjo Martín C González Ramírez MD Piñar-Morales R |
| author_sort | Barrero Hernández FJ |
| collection | DOAJ |
| description | Francisco Javier Barrero Hernández,1– 3 Ángel José Morales Lahoz,1 Cristina Serrano Gutiérrez,1 Elena López Fandila,1 Carolina Asenjo Martín,1 Maria Dolores González Ramírez,2 Raquel Piñar-Morales1– 3 1Department of Neurology, Hospital Clinico Universitario San Cecilio, Granada, Spain; 2Department of Medicine, Faculty of Medicine. University of Granada, Granada, Spain; 3Institute of Biosanitary Research: (IBS.Granada), Granada, SpainCorrespondence: Francisco Javier Barrero Hernández, Email fjbarreroh@ugr.esIntroduction: Generally, the choice of disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS) is based on aspects of efficacy and safety. However, due to the diversity of drugs and the different routes of administration, it is essential to know the experience and satisfaction of PwMS. Patient- reported outcomes (PROs) help us to optimize and improve adherence.Methods: Our objective with this cross-sectional, non-interventional study is to analyze satisfaction outcomes using the treatment satisfaction questionnaire for medication (TSQM) according to moderate or high efficacy of DMTs and the relationship with demographic, clinical and quality of life (QoL) aspects.Results: PwMS receiving high-efficacy DMTs show greater overall satisfaction, but not in the other TSQM subscales. The route of administration did not show differences in treatment satisfaction. The best QoL scores were observed in patients treated with oral DMTs compared to injectables or infusions.Discussion: The efficacy of DMT is a significant predictor of overall satisfaction. Quality of life has a minimal impact on overall satisfaction. EDSS, treatment duration and fatigue (MFIS) were not significant predictors of satisfaction outcomes. The knowledge provided by the PROs allows healthcare professionals to better understand the preferences and needs of PwMS, adjusting therapeutic strategies, improving patient experience and treatment effectiveness.Keywords: quality of life, relapsing remitting multiple sclerosis, fatigue, patient- reported outcomes, treatment satisfaction, disease-modifying treatment |
| format | Article |
| id | doaj-art-9397e372f5024cf9ba35599d69b5b7b4 |
| institution | DOAJ |
| issn | 1177-889X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj-art-9397e372f5024cf9ba35599d69b5b7b42025-08-20T02:41:33ZengDove Medical PressPatient Preference and Adherence1177-889X2025-03-01Volume 19715727101395Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple SclerosisBarrero Hernández FJMorales Lahoz ÁJSerrano Gutiérrez CLópez Fandila EAsenjo Martín CGonzález Ramírez MDPiñar-Morales RFrancisco Javier Barrero Hernández,1– 3 Ángel José Morales Lahoz,1 Cristina Serrano Gutiérrez,1 Elena López Fandila,1 Carolina Asenjo Martín,1 Maria Dolores González Ramírez,2 Raquel Piñar-Morales1– 3 1Department of Neurology, Hospital Clinico Universitario San Cecilio, Granada, Spain; 2Department of Medicine, Faculty of Medicine. University of Granada, Granada, Spain; 3Institute of Biosanitary Research: (IBS.Granada), Granada, SpainCorrespondence: Francisco Javier Barrero Hernández, Email fjbarreroh@ugr.esIntroduction: Generally, the choice of disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS) is based on aspects of efficacy and safety. However, due to the diversity of drugs and the different routes of administration, it is essential to know the experience and satisfaction of PwMS. Patient- reported outcomes (PROs) help us to optimize and improve adherence.Methods: Our objective with this cross-sectional, non-interventional study is to analyze satisfaction outcomes using the treatment satisfaction questionnaire for medication (TSQM) according to moderate or high efficacy of DMTs and the relationship with demographic, clinical and quality of life (QoL) aspects.Results: PwMS receiving high-efficacy DMTs show greater overall satisfaction, but not in the other TSQM subscales. The route of administration did not show differences in treatment satisfaction. The best QoL scores were observed in patients treated with oral DMTs compared to injectables or infusions.Discussion: The efficacy of DMT is a significant predictor of overall satisfaction. Quality of life has a minimal impact on overall satisfaction. EDSS, treatment duration and fatigue (MFIS) were not significant predictors of satisfaction outcomes. The knowledge provided by the PROs allows healthcare professionals to better understand the preferences and needs of PwMS, adjusting therapeutic strategies, improving patient experience and treatment effectiveness.Keywords: quality of life, relapsing remitting multiple sclerosis, fatigue, patient- reported outcomes, treatment satisfaction, disease-modifying treatmenthttps://www.dovepress.com/clinical-practice-evidence-of-treatment-satisfaction-with-moderate-and-peer-reviewed-fulltext-article-PPAquality of liferelapsing remitting multiple sclerosisfatiguepatient- reported outcomestreatment satisfactiondisease-modifying treatment. |
| spellingShingle | Barrero Hernández FJ Morales Lahoz ÁJ Serrano Gutiérrez C López Fandila E Asenjo Martín C González Ramírez MD Piñar-Morales R Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis Patient Preference and Adherence quality of life relapsing remitting multiple sclerosis fatigue patient- reported outcomes treatment satisfaction disease-modifying treatment. |
| title | Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis |
| title_full | Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis |
| title_fullStr | Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis |
| title_full_unstemmed | Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis |
| title_short | Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis |
| title_sort | clinical practice evidence of treatment satisfaction with moderate and high efficacy drugs in multiple sclerosis |
| topic | quality of life relapsing remitting multiple sclerosis fatigue patient- reported outcomes treatment satisfaction disease-modifying treatment. |
| url | https://www.dovepress.com/clinical-practice-evidence-of-treatment-satisfaction-with-moderate-and-peer-reviewed-fulltext-article-PPA |
| work_keys_str_mv | AT barrerohernandezfj clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT moraleslahozaj clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT serranogutierrezc clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT lopezfandilae clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT asenjomartinc clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT gonzalezramirezmd clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis AT pinarmoralesr clinicalpracticeevidenceoftreatmentsatisfactionwithmoderateandhighefficacydrugsinmultiplesclerosis |